Status:
UNKNOWN
Obstructive Sleep Apnea (OSA) and Metabolic Syndrome: Role of Oxidative Stress
Lead Sponsor:
National Institute on Aging (NIA)
Collaborating Sponsors:
University of Pittsburgh
Conditions:
Obstructive Sleep Apnea
Metabolic Syndrome X
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this study is to define the mechanism(s) through which Obstructive Sleep Apnea/Hypopnea (OSAH) promotes abnormal metabolic processes which characterize the metabolic syndrome. The inves...
Detailed Description
The metabolic syndrome has been defined as insulin resistance, central obesity, systemic hypertension and dyslipidemia and is associated with increased cardiovascular (CV) risk. Obstructive Sleep Apne...
Eligibility Criteria
Inclusion
- Nonsmoker for at least 6 months
- No history of movement disorder during sleep, or circadian rhythm disorder
- No excessive daytime sleepiness
- No history of chronic insomnia, mood or affective disorders or other psychiatric disorders
- Participants maintain a regular sleep-wake pattern with an estimated sleep time between 6.5 and 10 hours per night
- Ability and willingness to avoid meat with its juice (gravy), cured or smoked foods and green leafy vegetables, fruit and fruit juices, food products or vitamin supplements containing vitamin C and E supplements for at least 1 day prior to and during the study periods
- Consumption of less than 1 alcoholic beverage per day
- Ability to understand the study and sign the informed consent
- Not currently pregnant
- Live within 45 miles of the study site
- No uncontrolled hypertension (blood pressure greater than 150/100)
- Willingness to avoid caffeinated beverages and food during the study protocol period
- Participants With Sleep Apnea:
- Diagnosis of severe Obstructive Sleep Apnea and Hypopnea (OSAH) (RDI greater than 25) and initiation of positive airway pressure therapy more than 1 month before enrollment
- Must have had an adequate clinical titration of positive airway pressure therapy
- On positive airway pressure for at least 1 month with adherence of more than 5 hours of use per day with no history of snoring, no excessive daytime sleepiness and no reported observed apnea episodes on positive airway pressure
- Willing to sleep with and without positive airway pressure therapy as required by the study protocol
Exclusion
- History or physical examination evidence of active coronary artery disease, heart failure, cardiomyopathy, syncope, potentially life-threatening arrhythmia, stroke, transient ischemic attack, neurologic impairment, renal, hepatic or thyroid disease (unless on stable thyroid replacement medication); history of diabetes mellitus; history of cancer within the past 10 years (other than basal cell carcinoma), venous thrombosis, or collagen-vascular disease or other condition that the investigators believe may be exacerbated by participation in the stud
- History of awakening with angina pectoris
- Currently taking medication for mood or affective disorders or that affect heme metabolism, autonomic nervous system or sleep architecture, or prescribed nitrates or corticosteroids
- Physician-diagnosed Alzheimer's or non-Alzheimer's dementia
- Previous surgery for sleep apnea
- Hematocrit less than 32
- Use of a hearing aid in one or both ears
- History of a bleeding disorder, abnormal bleeding, or known adverse reaction to heparin
- Inability to obtain venous blood or a low likelihood of obtaining venous access as required in this protocol
- History of migraine of a nature, frequency, and severity that, in the investigators' judgement, may be precipitated by participation in the protocol
- Presence of a potentially life-threatening dysrhythmia on the clinical diagnostic PSG
- History of motor vehicle accident due to falling asleep; not currently employed as a driver in the transportation industry or an airplane pilot
- Lipid-lowering agents for participants without a history of sleep apnea
- Individuals on positive airway pressure therapy for sleep apnea must not have lost more than 10 pounds of weight since starting this treatment
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2008
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00177892
Start Date
September 1 2003
End Date
August 1 2008
Last Update
March 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States, 15261